Funding

Differential Bio funding news – Munich-based Differential Bio Secures €2 Million in Pre-Seed Funding

Mar 26, 2025 | By Startuprise

Differential Bio funding news - Munich-based Differential Bio Secures €2 Million in Pre-Seed Funding

Differential Bio, a Munich-based AI biotech startup, emerged from stealth with €2 million in pre-seed funding to redefine biomanufacturing. Its Virtual Scale-up Platform seamlessly integrates advanced microbiology, lab automation, and artificial intelligence, unlocking unprecedented speed and efficiency to optimize and scale bioprocesses.

SUMMARY

  • Differential Bio, a Munich-based AI biotech startup, emerged from stealth with €2 million in pre-seed funding to redefine biomanufacturing.
  • Differential Bio is integrating scale-down experiments with AI-based modeling to optimize how industry-relevant microbes grow ("biomass fermentation") and produce ("precision fermentation").

By eliminating critical bottlenecks, Differential Bio is not just improving biomanufacturing—it’s transforming it into a smarter, faster, and more scalable industry.

The funding round was led by Ananda Impact Ventures and ReGen Ventures with participation from Carbon13, Climate Capital, Better Ventures, CDTM Ventures, alongside a prominent group of angel investors.

Tackling Biomanufacturing’s Biggest Challenges

Biomanufacturing stands at a pivotal moment today. Recent global disruptions—such as skyrocketing cocoa prices due to supply chain volatility, widespread egg shortages driven by avian flu outbreaks, and regulatory bans on synthetic dyes amid health concerns—have exposed the fragility of traditional production systems.

Read also - EcoDataCenter funding news – EcoDataCenter Secures €450 Million in Funding

These events highlight an urgent need for sustainable, resilient alternatives. Biomanufacturing, which harnesses biological systems like microbial cells to produce everything from food ingredients to pharmaceuticals, offers a promising solution. Yet, despite its potential, the industry faces a significant hurdle: scaling bioprocesses from lab to industrial levels is notoriously slow and prohibitively expensive.

Christian Spier, CEO of Differential Bio said, “Biomanufacturing holds the key to a regenerative future, but scaling these processes remains a major bottleneck for the industry, reflecting on the average 5-10 years and $100-500m it takes to develop novel bioproducts, but we are here to change that, empowering biomanufacturers with cutting-edge tools to slash development timelines and costs, bringing bio-based products to market faster than ever before”.

Differential Bio’s Virtual Scale-up Platform integrates three core innovations: advanced microbiology to miniaturize fermentation processes, robotics to automate lab workflows and generate high-quality data, and AI algorithms to simulate and optimize bioprocesses virtually.

This synergy minimizes reliance on costly and resource-intensive physical experiments, delivering precise insights into critical factors such as biomass growth rates, metabolite production, and cell viability. The outcome? Faster optimization cycles, significant cost reductions through automation, and enhanced profitability thanks to higher yields and improved process efficiency.

Differential Bio has already demonstrated the transformative power of its technology with clients and partners. In the probiotics industry—a fast-growing segment of the health and wellness industry—the company tackled a dual challenge: transitioning a microbial strain from an animal-based to a plant-based growth medium while maintaining performance.

Using its Virtual Scale-up Platform, Differential Bio not only achieved this sustainability milestone but also delivered remarkable results: a 4x increase in biomass yield - boosting production efficiency - and a 16% reduction in production costs.

CSO Dong Zhao explained said, "These findings were presented at a leading probiotics conference in Copenhagen earlier this year, earning widespread attention from industry leaders. The case study underscored a crucial point: sustainability and profitability are not mutually exclusive. This project showcased the platform’s ability to handle multi-objective optimizations, We proved that sustainable biomanufacturing can enhance performance and cut costs simultaneously—no compromises required.”

Biomanufacturing is poised to revolutionize how we produce goods across multiple industries, including food and beverages, cosmetics, chemicals, and even textiles and materials. Experts estimate that up to 60% of the physical inputs in these sectors could eventually be manufactured biologically.

With global biomanufacturing capacity expected to surge 10 to 20 times over the next few decades, the demand for efficient scaling solutions has never been greater - and Differential Bio is well-positioned at the forefront of this shift.

Bernd Klosterkemper, Partner at Ananda Impact Ventures said, “The Differential team immediately stood out to us with their exceptional combination of deep technical expertise, innovative scientific approach, and a visionary drive to deliver impactful solutions at scale, We believe their technology will redefine biomanufacturing by enabling faster, more efficient scaling of bio-based processes, accelerating the global transition to a sustainable, green, and circular economy.”

Tom McQuillen Partner at ReGen Ventures said, “Biomanufacturing is constrained by a scaling crisis. By leveraging machine learning on extensive phenotypic and bioprocess data, Differential has the potential to redefine biomanufacturing at scale by providing a step function reduction in cost and time to commercialization, Chris, Dong and Martin have a daring ambition to transform biomanufacturing and we feel honored to partner in the journey”.

About Differential Bio

Differential Bio is integrating scale-down experiments with AI-based modeling to optimize how industry-relevant microbes grow ("biomass fermentation") and produce ("precision fermentation"). By optimizing bioprocesses and growth conditions, the company is not only increasing their clients' R&D efficiency but alsodramatically improving bioproduction outcomes such as yield, cost efficiency, and product quality.

Recommended Stories for You